Physician profile
Samara Epps Mcelroy
NPI 1235431198
$3,840.81
in general payments reported to CMS, 2019-2025
31 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.51 · 2020: $19.31 · 2021: $151 · 2022: $802 · 2023: $1,166 · 2024: $1,187 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,788.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.59 | 2021-2025 | |
| Lilly USA, LLC | $377.04 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $310.78 | 2019-2025 | |
| Novo Nordisk INC | $281.13 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $276.27 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Novartis Pharmaceuticals Corporation | $273.52 | 2022-2025 | |
| Amgen INC. | $258.19 | 2021-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals Lp | $212.78 | 2022-2024 | Fasenra, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.32 | 2021-2024 | Jardiance |
| Axsome Therapeutics, INC. | $102.02 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $76.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $64.32 | 2024-2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $55.40 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.38 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.59 | 2023-2025 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $39.97 | 2025 | Inceptiv |
| Xeris Pharmaceuticals, INC. | $37.88 | 2024-2025 | Keveyis |
| Astellas Pharma US INC | $36.14 | 2022-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $33.35 | 2022-2024 | Eliquis |
| Neos Therapeutics, Lp | $31.49 | 2019 | |
| Merck Sharp & Dohme LLC | $28.91 | 2022 | |
| Edwards Lifesciences Corporation | $27.81 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Dexcom, INC. | $24.38 | 2024 | Dexcom G6 Transmitter |
| Nevro Corp. | $21.16 | 2022 | |
| Allergan, INC. | $19.31 | 2020 | |
| Sumitomo Pharma America, INC. | $17.12 | 2024 | Gemtesa |
| Kestra Medical Technology Services, INC. | $17.00 | 2024 | Assure Wcd |
| Sunovion Pharmaceuticals INC. | $16.51 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.42 | 2024 | Zoryve |
| Ironwood Pharmaceuticals, INC | $13.81 | 2021 | |
| Amarin Pharma, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samara Mcelroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.